Induction of spontaneous neo-angiogenesis and tube formation in human endometrial stem cells by bioglass

Abstract

Endothelial dysfunction is a broad pathological disorder of the endothelium (innermost layer of blood vessels) which is assigned by vasoconstriction, thrombosis and ischemic diseases, alone or with other disorders such as coronary artery disease, hypertension and atherosclerosis. The fundamental imperfection of endothelial layer injury due to decrease in the number of functional endothelial progenitor cells and inhibition of endothelial progenitor cell differentiation, resulting into impairment of angiogenesis, vasculogenesis, tube formation properties and endothelial regeneration. Multiple significant therapeutic achievements in impediment and treatment of vascular diseases include the use of antithrombotic agents, statin class of drugs, lifestyle changes, and revascularization therapies. Nevertheless, a certain number of patients with endothelial dysfunction disease are resistant to the usual therapies, so new therapeutic strategies for endothelial dysfunction disease are urgently needed. Recent studies show that stem cell-based therapy has important promise for repair and treatment of vascular dysfunction. In this study, we describe a novel choice for treatment of endothelial dysfunction in vascular regenerative medicine via the human endometrial stem cell culture (as a new source for the increasing the number of endothelial progenitor cells) with bioglass (angiogenic agent) to investigate the enhancing expression of CD34, CD31 and gene markers of endothelial progenitor cells and endothelial cells. In the end, application of immunoprivileged, readily available sources of adult stem cells like human endometrial stem cells with bioglass would be a promising strategy to increase the number of endothelial progenitor cells and promote spontaneous angiogenesis needed in endothelial layer repair and regeneration.

Stem Cell Therapy in Limb Ischemia: State-of-Art, Perspective, and Possible Impacts of Endometrial-Derived Stem Cells

“… Chan et al (2004) also confirmed the presence of clonogenic stem cell populations in the endometrium tissue ( Chan et al, 2004 ). We already proved that this mentioned regenerative capacity in the endometrium tissue is due to the presence of EnSCs that were demonstrated to be immuno-privileged in comparison with other cell types ( Shamosi et al, 2015 ), shedding new light on cell-based therapies and rendering these cells a promising resource in limb tissue regeneration ( Figure 3 ). The human endometrium is a highly regenerative tissue due to the fact that a complete regeneration of the uterus can be achieved after almost total resection of the endometrium, with the renovated endometrium still maintaining its ability to support gestation ( Murphy et al, 2008 ).…”

“…This therapeutic response is triggered through the stem cell differentiation to endothelial cells and secreting various types of pro-angiogenic factors into the injured tissue microenvironment ( Khodayari et al, 2019 ). Based on experimental observations, the MSCs, EPCs, and EnSCs are the cells that show both the responses after transplantation ( Shamosi et al, 2015 ; Bouland et al, 2021 ), while the MNCs have no significant differentiation potential, and it seems their efficacy is induced via regulating the ischemic tissue environment ( Li et al, 2006 ). These facts raise the possibility that releasing pro-angiogenic factors can be the main factor for inducing therapeutic angiogenesis into the injured limb.…”

Fabrication of hydrogel based nanocomposite scaffold containing bioactive glass nanoparticles for myocardial tissue engineering

“…The results indicate that supernatant of cultures on Gel/Col/BG scaffold contained significantly higher amounts of VEGF compared to culture son Gel/Col scaffold (2.14 folds, P<0.001). This finding indicates that BG inclusion in hydrogel scaffold triggers expression of VEGF and subsequently promotes angiogenesis [30].…”

Mesoporous Bioactive Glasses in Cancer Diagnosis and Therapy: Stimuli‐Responsive, Toxicity, Immunogenicity, and Clinical Translation

“…[24,28,32] These unique features (e.g., biodegradability, biocompatibility, drugdelivery, osteogenic, and angiogenic potential) make MBGs desirable candidates for biomedical applications including cancer therapy. [41,52,53] In recent years, many preclinical studies have developed stable MBGs with controlled delivery of drugs, desirable biosafety, and efficient suppression of tumor growth to pave the way for clinical applications. [34,[54][55][56] Besides MBG applications in different cancer types, special consideration has been devoted to bone cancer rooting in the therapeutic/regenerative effects of released ions (Si, Ca, and P) from the MBGs' structure.…”

“…[ 24,28,32 ] These unique features (e.g., biodegradability, biocompatibility, drug‐delivery, osteogenic, and angiogenic potential) make MBGs desirable candidates for biomedical applications including cancer therapy. [ 41,52,53 ] In recent years, many preclinical studies have developed stable MBGs with controlled delivery of drugs, desirable biosafety, and efficient suppression of tumor growth to pave the way for clinical applications. [ 34,54–56 ]…”